Dermatology
| Atopic Dermatitis
Dermatology
Atopic Dermatitis
Efficacy and safety of lebrikizumab in moderate-to-severe atopic Dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)
book_2
Source:
EADV Congress 2022 - Oral session
calendar_today
Published on Medfyle:
September 2022
import_contacts
4
min
In this medfyle
New 52-week data from the ADvocate trials show maintained improvement of the signs and symptoms of AD, with a safety profile consistent with previously published data.
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a highlights summary of an oral session given at the EADV 2022 - 31st Congress and presented by:
Dr. Andrew Blauvelt
Oregon Medical Research Center
Portland, OR, United States
The content is produced by Infomedica, the official reporting partner of EADV 2022.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
